Short answer
ArriVent BioPharma, Inc. (AVBP) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). First U.S. patient dosed in Phase 1 ARR-002 trial.
ArriVent BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- First U.S. patient dosed in Phase 1 ARR-002 trial
- ARR-002 targets ovarian and endometrial cancers
- Potential first-in-class MUC16/NaPi2b dual-target tetravalent antibody-drug conjugate
- Clinical launch creates initial human data catalyst for ArriVent BioPharma valuation
Item 8.01 · Other Events
- Item 8.01 incorporates most of the Item 7.01 press release into the filing
- Investor-relevant details depend on the referenced press release, excluding its second and third paragraphs
Item EX-99.1 · Exhibit EX-99.1
- First patient dosed in Phase 1 ARR-002 trial, initiating clinical validation of ArriVent’s second ADC program
- Trial targets advanced or metastatic ovarian and endometrial cancers, expanding pipeline beyond lung and gastrointestinal cancers
- ARR-002 uses dual MUC16/NaPi2b targeting and a tetravalent 2+2 format, intended to address heterogeneous tumor expression
- Shanghai Allist holds exclusive Greater China rights, while ArriVent retains rights elsewhere
- Key near-term catalysts: safety, tolerability, pharmacokinetic and efficacy data from NCT07755436
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ArriVent BioPharma, Inc. 8-K filings
Get the next AVBP 8-K as it lands
Follow AVBP for push alerts, or ask the research agent what this filing means.